MedPath
HSA Approval

CLARICLEAR NASAL SPRAY 0.05%

SIN02656P

CLARICLEAR NASAL SPRAY 0.05%

CLARICLEAR NASAL SPRAY 0.05%

April 27, 1989

BAYER (SOUTH EAST ASIA) PTE LTD

BAYER (SOUTH EAST ASIA) PTE LTD

Regulatory Information

BAYER (SOUTH EAST ASIA) PTE LTD

BAYER (SOUTH EAST ASIA) PTE LTD

Therapeutic

General Sale List

Formulation Information

SPRAY

**DOSAGE AND ADMINISTRATION: For adults and children six years of age and older:** Two or three sprays into each nostril twice daily, morning and evening. With the head upright, place the sprays nozzle into the nostril without completely occluding the nostril. During each administration, the patient should bend his head slightly forward and spray the dose into each nostril by squeezing the bottle rapidly and strongly.

NASAL

Medical Information

**INDICATIONS:** Clariclear® Nasal Spray is indicated for symptomatic relief of nasal and nasal pharyngeal congestion due to the common cold, sinusitis, hay fever or other upper respiratory allergies.

**CONTRAINDICATIONS:** Oxymetazoline-containing nasal sprays should not be used: - in patients with known hypersensitivity to oxymetazoline or other adrenergic agents, or to any component of the medicinal product; - in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs in the previous two weeks; - in patients with narrow-angle glaucoma; - in patients after trans-sphenoidal hypophysectomy; - where there is inflammation of the skin and mucosa of the nasal vestibule and encrustation (rhinitis sicca); - in patients with acute cardiovascular disease or cardiac asthma; - in patients with severe high blood pressure.

R01AA05

oxymetazoline

Manufacturer Information

BAYER (SOUTH EAST ASIA) PTE LTD

Delpharm Montréal INC

Active Ingredients

OXYMETAZOLINE HCl

0.500 mg/ml

Oxymetazoline

Documents

Patient Information Leaflets

1.4.4_PIL_proposed.pdf

Approved: June 30, 2022

Download
© Copyright 2025. All Rights Reserved by MedPath